相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Insulin Acutely Inhibits Intestinal Lipoprotein Secretion in Humans in Part by Suppressing Plasma Free Fatty Acids
Mirjana Pavlic et al.
DIABETES (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes
David A. D'Alessio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Antonio Cervera et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans
Helene Duez et al.
CIRCULATION (2008)
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
Koichiro Azuma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Sandeep Bansal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Borge G. Nordestgaard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes
Jean-Charles Hogue et al.
JOURNAL OF LIPID RESEARCH (2007)
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
Bogdan Balas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
GLP-1 and type 2 diabetes: physiology and new clinical advances
Murielle M. J. Combettes
CURRENT OPINION IN PHARMACOLOGY (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Intestinal insulin resistance and aberrant production of apolipoprotein b48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia - Evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine
LM Federico et al.
DIABETES (2006)
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
K Al Majali et al.
DIABETOLOGIA (2006)
Fatty acids and insulin resistance in muscle and liver
P Kovacs et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats
XF Qin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2005)
Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes
JPH Van Wijk et al.
DIABETES CARE (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes
GD Tan et al.
DIABETOLOGIA (2005)
Determination of apolipoprotein B-48 in serum by a sandwich ELISA
M Kinoshita et al.
CLINICA CHIMICA ACTA (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Elevated remnant-like particle cholesterol concentration - A characteristic feature of the atherogenic lipoprotein phenotype
TB Twicker et al.
CIRCULATION (2004)
Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus
F Abbasi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: Studies in insulin-resistant and insulin-sensitized Syrian Golden hamsters
GF Lewis et al.
ENDOCRINOLOGY (2004)
Intimal retention of cholesterol derived from apolipoprotein B100-and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits
SD Proctor et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes
J Vakkilainen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study
EJ Schaefer et al.
DIABETES CARE (2002)
Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes
GF Lewis et al.
ENDOCRINE REVIEWS (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins
CL Elsegood et al.
CLINICAL SCIENCE (2001)
分享论文
